安羅替尼治療晚期肝癌患者的效果

厲鋒　鮑樂　丁軼人　趙鴻鷹　李文廣　袁磊

摘要：目的 ?觀察安羅替尼治療晚期肝癌患者的臨床效果及安全性。方法 ?回顧性分析2019年2月～2020年3月在我院診治的50例晚期肝癌患者臨床資料，采用隨機數字表法將其分為對照組（n=26）和研究組（n=24）。對照組采用索拉非尼治療，研究組采用安羅替尼治療，比較兩組臨床治療總有效率、病情控制率、肝功能指標[丙氨酸氨基轉移酶（ALT）、白蛋白（ALB）、總膽紅素（TBIL）]、血清血管內皮生長因子（VEGF）水平、不良反應發生情況以及中位生存時間。結果 ?研究組病情控制率為29.17%、總有效率為75.00%，與對照組的34.62%、73.08%比較，差異無有統計學意義（P>0.05）;治療后，兩組ALT、ALB均低于治療前，差異有統計學意義（P<0.05），TBIL與治療前比較，差異無統計學意義（P>0.05）;研究組ALT、ALB、TBIL與對照組比較，差異無統計學意義（P>0.05）;研究組手足綜合征、蛋白尿、高血壓、腹瀉、乏力、皮疹、脫發不良反應發生率均低于對照組，差異有統計學意義（P<0.05）;隨訪3個月，研究組中位生存時間為（26.11±1.38）個月，長于對照組的（22.40±2.27）個月，差異有統計學意義（P<0.05）。結論 ?安羅替尼治療晚期肝癌效果確切，總有效率和疾病控制率與索拉非尼基本一致，但是安羅替尼不良反應少，可提高患者耐受性，促進治療順利進行，進一步延長患者生存時間。

關鍵詞：安羅替尼;晚期肝癌;病情控制率

中圖分類號：R735.7 ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?文獻標識碼：A ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?DOI：10.3969/j.issn.1006-1959.2020.18.045

文章編號：1006-1959（2020）18-0138-03

Anlotinib in the Treatment of Patients with Advanced Liver Cancer

LI Feng1，BAO Le2，DING Yi-ren3，ZHAO Hong-ying1，LI Wen-guang1，YUAN Lei2

（Department of Oncology1，Department of Intervention2，Department of Surgery3，Xuzhou Cancer Hospital，

Xuzhou 221000，Jiangsu，China）

Abstract：Objective ?To observe the clinical effect and safety of Anlotinib in the treatment of patients with advanced liver cancer.Methods ?The clinical data of 50 patients with advanced liver cancer diagnosed and treated in our hospital from February 2019 to March 2020 were retrospectively analyzed， and they were divided into a control group （n=26） and a study group （n=24） using a random number table method.The control group was treated with sorafenib and the study group was treated with anlotinib. The total effective rate， disease control rate， liver function indexes of the two groups were compared between the two groups. [Alanine aminotransferase （ALT）， albumin （ALB） ， Total bilirubin （TBIL）]， serum vascular endothelial growth factor （VEGF） levels， occurrence of adverse reactions， and median survival time.Results ?The disease control rate of the study group was 29.17% and the total effective rate was 75.00.Compared with 34.62% and 73.08% of the control group， the difference was not statistically significant （P>0.05）; after treatment， the ALT and ALB of the two groups were both low before treatment， the difference was statistically significant （P<0.05）. There was no statistically significant difference between TBIL and before treatment （P>0.05）;There was no significant difference in ALT， ALB， TBIL between the study group and the control group （P>0.05）; the incidence of adverse reactions such as hand-foot syndrome， proteinuria， hypertension， diarrhea， fatigue， rash， and alopecia in the study group were lower than those of the control group Group， the difference was statistically significant （P<0.05）; follow-up for 3 months， the median survival time of the study group was （26.11±1.38） months， longer than the control group （22.40±2.27） months， the difference was statistically significant （P<0.05）.Conclusion ?Anlotinib had a definite effect in the treatment of advanced liver cancer. The total effective rate and disease control rate were basically the same as those of sorafenib. However， there were few adverse reactions of Anlotinib， which could improve patient tolerance， promote smooth treatment， and further extend the patient survival time.

Key words：Anlotinib;Advanced liver cancer;Disease control rate

晚期肝癌（advanced liver cancer）是臨床常見的惡性腫瘤，相關數據顯示[1，2]，肝癌是惡性腫瘤死亡原因第2位。目前，臨床常用治療方法有靶向治療、免疫治療和化療[3]，可延長生存期。隨著近年來醫學水平的不斷提高，靶向藥物治療是治療肝癌的一個突破。安羅替尼作為一種小分子多靶點酪氨酸激酶抑制劑藥物，為肝癌靶向治療提供了選擇，研究表明[4]，將安羅替尼應用于各種癌癥治療中均可取得一定的療效，但其具體療效及安全性還需進一步研究。本研究結合2019年2月～2020年3月我院診治的50例晚期肝癌患者臨床資料，研究安羅替尼治療晚期肝癌患者的臨床效果及安全性，現報道如下。